Have a feature idea you'd love to see implemented? Let us know!

FBIO Fortress Biotech Inc

Price (delayed)

$1.73

Market cap

$39.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.23

Enterprise value

$46.63M

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in ...

Highlights
Fortress Biotech's EPS has surged by 80% YoY and by 47% QoQ
FBIO's net income has soared by 58% YoY and by 25% QoQ
The gross profit has surged by 69% year-on-year but it has declined by 2.2% since the previous quarter
FBIO's revenue is up by 32% year-on-year but it is down by 2.9% since the previous quarter
The company's equity fell by 22% QoQ and by 3.4% YoY
The debt has increased by 6% YoY

Key stats

What are the main financial stats of FBIO
Market
Shares outstanding
22.81M
Market cap
$39.47M
Enterprise value
$46.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.93
Price to sales (P/S)
0.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.56
Earnings
Revenue
$82.62M
EBIT
-$30.85M
EBITDA
-$23.17M
Free cash flow
-$92.97M
Per share
EPS
-$3.23
Free cash flow per share
-$5.08
Book value per share
$0.9
Revenue per share
$4.51
TBVPS
$6.93
Balance sheet
Total assets
$145.69M
Total liabilities
$160.28M
Debt
$85.42M
Equity
$17.88M
Working capital
$27.89M
Liquidity
Debt to equity
4.78
Current ratio
1.37
Quick ratio
1.18
Net debt/EBITDA
-0.31
Margins
EBITDA margin
-28%
Gross margin
68.8%
Net margin
-49.2%
Operating margin
-118.3%
Efficiency
Return on assets
-31.5%
Return on equity
-246.7%
Return on invested capital
-59.1%
Return on capital employed
-44%
Return on sales
-37.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FBIO stock price

How has the Fortress Biotech stock price performed over time
Intraday
-2.81%
1 week
-4.42%
1 month
24.46%
1 year
-4.42%
YTD
-42.52%
QTD
19.72%

Financial performance

How have Fortress Biotech's revenue and profit performed over time
Revenue
$82.62M
Gross profit
$56.82M
Operating income
-$97.73M
Net income
-$40.69M
Gross margin
68.8%
Net margin
-49.2%
The gross profit has surged by 69% year-on-year but it has declined by 2.2% since the previous quarter
The net margin has soared by 68% YoY and by 23% QoQ
FBIO's operating margin has surged by 65% year-on-year and by 16% since the previous quarter
FBIO's net income has soared by 58% YoY and by 25% QoQ

Growth

What is Fortress Biotech's growth rate over time

Valuation

What is Fortress Biotech stock price valuation
P/E
N/A
P/B
1.93
P/S
0.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.56
Fortress Biotech's EPS has surged by 80% YoY and by 47% QoQ
The P/B is 31% less than the 5-year quarterly average of 2.8 but 7% more than the last 4 quarters average of 1.8
The company's equity fell by 22% QoQ and by 3.4% YoY
The P/S is 85% below the 5-year quarterly average of 2.6 and 5% below the last 4 quarters average of 0.4
FBIO's revenue is up by 32% year-on-year but it is down by 2.9% since the previous quarter

Efficiency

How efficient is Fortress Biotech business performance
Fortress Biotech's return on sales has surged by 69% YoY and by 21% QoQ
FBIO's return on invested capital is up by 48% year-on-year and by 37% since the previous quarter
The company's return on equity rose by 21% QoQ and by 5% YoY
The ROA has grown by 19% year-on-year and by 17% since the previous quarter

Dividends

What is FBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FBIO.

Financial health

How did Fortress Biotech financials performed over time
The total assets is 9% less than the total liabilities
FBIO's quick ratio is up by 42% YoY and by 8% QoQ
Fortress Biotech's current ratio has increased by 38% YoY and by 3% from the previous quarter
The debt to equity is up by 28% since the previous quarter and by 10% year-on-year
The company's equity fell by 22% QoQ and by 3.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.